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OBJECTIVE — This 24-week trial assessed the efﬁcacy and safety of saxagliptin as add-on
therapyinpatientswithtype2diabeteswithinadequateglycemiccontrolwithmetforminalone.
RESEARCH DESIGN AND METHODS — This was a randomized, double-blind, pla-
cebo-controlled study of saxagliptin (2.5, 5, or 10 mg once daily) or placebo plus a stable dose
of metformin (1,500–2,500 mg) in 743 patients (A1C 7.0 and 10.0%). Efﬁcacy analyses
were performed using an ANCOVA model using last observation carried forward methodology
on primary (A1C) and secondary (fasting plasma glucose [FPG] and postprandial glucose [PPG]
area under the curve [AUC]) end points.
RESULTS — Saxagliptin (2.5, 5, and 10 mg) plus metformin demonstrated statistically sig-
niﬁcant adjusted mean decreases from baseline to week 24 versus placebo in A1C (0.59,
0.69,and0.58vs.0.13%;allP0.0001),FPG(14.31,22.03,and20.50vs.1.24
mg/dl; all P  0.0001), and PPG AUC (8,891, 9,586, and 8,137 vs. 3,291 mg   min/dl;
all P  0.0001). More than twice as many patients achieved A1C 7.0% with 2.5, 5, and 10 mg
saxagliptin versus placebo (37, 44, and 44 vs. 17%; all P  0.0001). -Cell function and
postprandial C-peptide, insulin, and glucagon AUCs improved in all saxagliptin treatment
groupsatweek24.Incidenceofhypoglycemicadverseeventsandweightreductionsweresimilar
to those with placebo.
CONCLUSIONS — Saxagliptin once daily added to metformin therapy was generally well
tolerated and led to statistically signiﬁcant improvements in glycemic indexes versus placebo
added to metformin in patients with type 2 diabetes inadequately controlled with metformin
alone.
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S
axagliptin is a potent, selective
dipeptidyl peptidase-4 (DPP-4) in-
hibitor, speciﬁcally designed for ex-
tended inhibition of the DPP-4 enzyme
(1,2). DPP-4 rapidly cleaves and inacti-
vates the incretin hormones glucagon-
like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide
(GIP) (1). GLP-1 and GIP regulate blood
glucose homeostasis by stimulation of
glucose-dependent insulin secretion (3).
GLP-1 also delays gastric emptying and
inhibits glucagon secretion (3,4). In ro-
dents,GLP-1hasbeenshowntostimulate
-cell growth and differentiation and in-
hibit -cell apoptosis (5). Such an ap-
proach is needed because the majority of
patients with type 2 diabetes fail to
achieve recommended glycemic targets
with existing therapies, owing to safety
and tolerability issues and loss of efﬁcacy
over time (6).
Metformin is the most widely pre-
scribed ﬁrst-line agent for the management
of type 2 diabetes and is standard ﬁrst-line
pharmacotherapy, along with diet and ex-
ercise (7). Mechanistically, metformin re-
duces hepatic glucose production and
improves insulin sensitivity (8); however,
metforminaloneisfrequentlyinsufﬁcientto
maintain glycemic goals in the face of pro-
gressive-cellfailureandincreasinginsulin
resistance(9).Consequently,manypatients
require multiple oral antihyperglycemic
agents (9,10). Metformin works through
pathways complementary to saxagliptin,
and the combination of saxagliptin with
metformin may improve glycemic control
(11,12). Studies of other DPP-4 inhibitors
in combination with metformin over 24
weeks have demonstrated increased efﬁ-
cacyversusplacebo(13–15).Thesafetyand
efﬁcacyofsaxagliptinmonotherapyintreat-
ment-naive patients were established previ-
ously in a 12-week study across a dose
range of 2.5 to 40 mg/day. Signiﬁcant A1C
reductions were demonstrated in all active
treatment groups with maximal A1C efﬁ-
cacy observed with 5 mg saxagliptin. A test
for log-linear trend across the treatment
groups did not demonstrate a statistically
signiﬁcant dose response after 12 weeks of
treatment. The overall frequency of adverse
events was comparable across all treatment
groups and placebo and did not appear to
be dose related (16). The current trial
(CV181-014) examined the efﬁcacy and
safety of saxagliptin in combination with
metforminadministeredforupto24weeks
in patients with type 2 diabetes inade-
quately controlled with metformin alone.
RESEARCH DESIGN AND
METHODS— The study included
menandwomenwithtype2diabetesand
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and 10.0%) taking a stable dose of
metformin (1,500 but not 2,550 mg/
day) for at least 8 weeks before screening,
fasting C-peptide concentration 1.0 ng/
ml, age 18–77 years, and BMI 40
kg/m
2. Patients were excluded if they had
one or more of the following: symptoms
of poorly controlled diabetes, a history of
diabetic ketoacidosis or hyperosmolar
nonketotic coma, use of any other antihy-
perglycemic medication (8 weeks before)
orinsulin(1yearbefore),acardiovascular
event within 6 months before study entry
or New York Heart Association stage
III/IV congestive heart failure and/or
known left ventricular ejection fraction
40%, chronic or repeated intermittent
corticosteroidtreatment,ahistoryofalco-
hol or drug abuse within the previous
year, treatment with potent systemic cy-
tochrome P450 3A4 inhibitors or induc-
ers, active liver disease and/or clinically
signiﬁcant abnormalities on screening
tests of hepatic, renal, endocrine, meta-
bolic, or hematologic function, or assess-
ment of an immunocompromised state.
Women who were pregnant or breast-
feeding were also excluded.
This was a 24-week randomized,
four-arm, double-blind, placebo-
controlled study of patients with type 2
diabetes and inadequate glycemic control
with a stable dose of metformin mono-
therapy. Eligible patients enrolled in a
2-week,single-blind,dietaryandexercise
placebo lead-in period and received
open-label metformin at their prestudy
dose. After the lead-in period, eligible pa-
tients were randomly assigned 1:1:1:1
(permuted blocks stratiﬁed by site) by an
interactive voice response system to 2.5,
5, or 10 mg saxagliptin or placebo for 24
weeks in addition to their lead-in dose of
open-label metformin. Saxagliptin tablets
were identical in appearance to the
matchedplacebo.Patientscompletingthe
24-week treatment period or those who
met the rescue criteria (supplementary
Fig.A1,availableinanonlineappendixat
http://care.diabetesjournals.org/cgi/content/
full/dc08-1984/DC1) could enter the 42-
month long-term extension. Results will
be presented separately.
The study protocol was approved by
the institutional review board for each
participatingsiteandconductedinaccor-
dance with the Declaration of Helsinki
and Good Clinical Practice guidelines. All
participants provided informed consent.
The primary efﬁcacy outcome was
change from baseline in A1C to week 24.
Secondary end points included change
from baseline to week 24 in fasting
plasma glucose (FPG), the percentage of
patients at the glycemic target (deﬁned as
A1C 7.0%), and postprandial glucose
(PPG) 3-h area under the curve (AUC)
during a 75-g oral glucose tolerance test
(OGTT). Per protocol, the OGTT oc-
curred 30 min after administration of
study medication. Other efﬁcacy out-
comes included 2-h postprandial plasma
glucose (as measured during the OGTT),
percentage of patients at glycemic target
basedonpredeﬁnedA1Candglucoseval-
ues, and change from baseline to week 24
in fasting and postprandial plasma gluca-
gon, insulin, and C-peptide concentra-
tions; homeostasis model assessment
(HOMA)-2–derivedindexesofinsulinre-
sistance and -cell function (HOMA-2)
(17); and indexes of insulin sensitivity
and -cell function derived from the
OGTT (18,19). Safety monitoring in-
cluded assessments of reported adverse
events, data from physical examinations,
vital signs, and electrocardiograms and
standard laboratory measurements. Ad-
verse event reporting included investiga-
tor assessments for severity and
relationship to study medication. Hypo-
glycemia adverse events, including con-
ﬁrmed hypoglycemia (ﬁngerstick glucose
valueof50mg/dlassociatedwithsymp-
toms), were recorded.
Efﬁcacy analyses were performed on
the randomly assigned patient popula-
tion, consisting of randomly assigned pa-
tients who received at least one dose of
study medication and had a baseline and
at least one postbaseline measurement.
Each saxagliptin group was compared
with the placebo group for changes from
baseline to week 24 in continuous end
points using an ANCOVA with treatment
group as an effect and baseline value as a
covariate.Pointestimatesand95%CIsfor
the least-squares mean change within
eachtreatmentgroupaswellasthediffer-
ences in least-squares mean changes be-
tween each saxagliptin group and the
placebo group at week 24 were calcu-
lated. Sequential testing methodology
was used for secondary efﬁcacy end
points. Other continuous efﬁcacy vari-
ables were summarized using descriptive
statistics. The percentage of patients
achieving a therapeutic glycemic re-
sponseatweek24wascomparedbetween
eachsaxagliptingroupandthemetformin
plus placebo group using the Fisher’s ex-
act test. Last observation carried forward
methodology was used to handle missing
data. Safety analyses were performed on
the treated patient population, consisting
of randomly assigned patients who re-
ceived at least one dose of study medica-
tion. Efﬁcacy and safety measurements
obtainedafterrescuewerenotincludedin
analyses.With153patientspertreatment
group,therewouldbeatleast90%power
to detect a difference in A1C means of
0.5% between each saxagliptin plus met-
formin treatment group and the placebo
plusmetformingroup,presumingaSDof
1.2%. Assuming a dropout rate of 15%,
720 patients (180 per treatment group)
needed to be randomly assigned.
RESULTS— Patient disposition is
shown in supplementary Fig. A1. Of the
1,462 patients screened, 743 were ran-
domly assigned and received study treat-
mentand73%(543of743)completed24
weeks of treatment. A higher incidence of
discontinuations occurred in the placebo
group (37.4%) versus the saxagliptin
groups (22.9, 25.1, and 22.7% in the 25,
5, and 10 mg treatment groups, respec-
tively). Demographic and baseline char-
acteristicsweregenerallysimilaracrossall
treatment groups (supplementary Table
A1, available in an online appendix). For
the entire study population, mean age,
duration of diabetes, baseline A1C, and
baseline FPG were 54.6 years, 6.5 years,
8.0%, and 176 mg/dl, respectively. Daily
metformin doses at study entry ranged
from 500 to 2,550 mg. A history of being
overweight (64.47%) and hypertension
(59.08%) were the most commonly re-
ported diabetes-related conditions.
At week 24, treatment with saxaglip-
tin led to clinically and statistically signif-
icant reductions in A1C from baseline
versus metformin plus placebo (Table 1).
Differencesinadjustedmeanchangefrom
baseline versus placebo (95% CI) were
0.73% (0.92 to 0.53), 0.83%
(1.02 to 0.63), and 0.72% (0.91
to 0.52) for 2.5, 5, and 10 mg saxaglip-
tin, respectively (all P  0.0001). A1C
reductionsrelativetometforminpluspla-
cebo occurred in all saxagliptin treatment
groups at week 4, the earliest time point
assessed. Maximal A1C reductions were
reached at 12 weeks and were sustained
through 24 weeks (Fig. 1A).
The percentage of patients achieving
A1C7.0%wascomparablefor5and10
mg saxagliptin and higher than that for
2.5 mg saxagliptin (Table 1). A greater
percentage of patients taking saxagliptin
achieved A1C 7.0% versus those taking
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from metformin plus placebo (95% CI)
were 20.5% (10.6–30.5), 27.0% (17.0–
36.7), and 27.9% (17.7–37.7) for 2.5, 5,
and 10 mg saxagliptin, respectively (all
P  0.0001).
As in the overall population, treat-
ment with saxagliptin resulted in A1C re-
ductions from baseline to week 24 in all
A1C categories evaluated (baseline A1C
8.0, 8.0–9.0, or 9.0%). An inter-
actionoftreatmentwithbaselineA1Cwas
observed (P  0.05) with numerically
greater A1C reductions in the higher
baseline A1C categories for 2.5 and 5 mg
saxagliptin, whereas 10 mg saxagliptin
produced similar reductions in the two
higher A1C categories. A1C-lowering
effects were consistent across treatment
groups in all other tested subgroups in-
cluding duration of diabetes, geographic
region, sex, age, ethnicity, and BMI.
Statistically signiﬁcant FPG reduc-
tionsatweek24wereobservedinallsaxa-
gliptin treatment groups versus the
metformin plus placebo group (P 
0.0001)(Table1).Differencesinadjusted
mean change from baseline versus met-
formin plus placebo (95% CI) were
15.6 mg/dl (22.5 to 8.5), 23.3 mg/dl
(30.3 to 16.3), and 21.7 mg/dl
(28.8 to 14.7) for 2.5, 5, and 10 mg
saxagliptin, respectively. Differences be-
tween the effects of saxagliptin and met-
formin plus placebo on mean FPG were
apparentandnearmaximalasearlyasweek
2 in all saxagliptin treatment groups, with
the effect maintained throughout 24 weeks
(Fig. 1B).
Statistically signiﬁcant reductions
were seen in the PPG 3-h AUC during the
OGTT from baseline to week 24 in all
Table 1—Key glycemic efﬁcacy end points: changes from baseline
Efﬁcacy end point (week 24) PBO  MET
2.5 mg SAXA 
MET
5 mg SAXA 
MET
10 mg SAXA 
MET
n 179 192 191 181
A1C (%)
n 175 186 186 180
Adjusted change from baseline 0.13  0.07 0.59  0.07* 0.69  0.07* 0.58  0.07*
Difference vs. PBO 0.73  0.10 0.83  0.10 0.72  0.10
FPG (mg/dl)
n 176 188 187 181
Adjusted change from baseline 1.2  2.56 14.3  2.48* 22.0  2.49* 20.5  2.53*
Difference vs. PBO 15.6  3.56 23.3  3.57 21.7  3.60
A1C 7.0% (%)
n 175 186 186 180
n (%) 29 (16.6) 69 (37.1)* 81 (43.5)* 80 (44.4)*
Difference vs. PBO 20.5 27.0 27.9
PPG AUC (mg/dl)
n 131 150 146 148
Adjusted change from baseline 3,291  853.2 8,891  798.0* 9,586  810.5* 8,137  807.9*
Difference vs. PBO 5,599  1,168.2 6,294  1,176.8 4,845  1,175.1
PPG at 120 min (mg/dl)
n 135 155 155 152
Adjusted change from baseline 18.0  6.02 61.5  5.62* 58.2  5.62* 49.8  5.70*
Difference vs. PBO 43.5  8.23 40.3  8.23 31.8  8.31
PP glucagon AUC (pg   min/ml)
n 123 140 138 142
Adjusted change from baseline 4,315  332.7 5,511  311.9† 5,704  314.0‡ 5,816  309.6§
PP insulin AUC (U   min/ml)
n 118 137 133 136
Adjusted change from baseline 7  288.0 1,521  267.3* 1,079  271.4 1,635  268.3*
PP C-peptide AUC (ng   min/ml)
n 123 143 138 137
Adjusted change from baseline 66  32.9 231  30.5¶ 278  31.1* 249  31.2*
OGIS (ml/min   m
2)
n 117 135 135 136
Change from baseline 3.2  7.60 27.7  9.15 46.7  8.14 30.4  10.27
Insulinogenic index
n 109 124 126 121
Change from baseline 0.04  0.04 0.04  0.09 0.16  0.04 0.20  0.09
HOMA-2 (%)
n 166 175 180 173
Adjusted change from baseline 4.9  2.25 16.5  2.19 17.6  2.16 18.1  2.20
DataaremeansSEunlessindicatedotherwise.*P0.0001vs.placebo;†P0.0090vs.placebo;‡P0.0025vs.placebo;§P0.0010vs.placebo;P0.0063
vs. placebo; ¶P  0.0003 vs. placebo. MET, metformin; PBO, placebo; PP, postprandial; SAXA, saxagliptin.
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metformin plus placebo group (P 
0.0001)(Table1).Differencesinadjusted
mean change from baseline versus met-
formin plus placebo (95% CI) were
5,599mg min/dl(7,894to3,305),
6,294mg min/dl(8,606to3,983),
and 4,845 mg   min/dl (7,153 to
2,537) for 2.5, 5, and 10 mg saxaglip-
tin, respectively. Maximal A1C, FPG, and
PPGreductionswereobservedatthe5mg
saxagliptin dose, without evidence of a
dose-responserelationshipatgreaterthan
5 mg.
There was an overall decrease from
baseline in glucose concentration at all
timepointsoftheOGTTinthesaxagliptin
treatment groups at week 24 (Fig. 1C). At
the 120-min time point of the OGTT,
mean changes from baseline were greater
for 2.5, 5, and 10 mg saxagliptin versus
metformin plus placebo (63.9, 62.1,
and 40.7 mg/dl; all P  0.0001 versus
21.0mg/dlforplacebo).The95%CIfor
the mean change from baseline excluded
zero in all treatment groups.
Atalldoses,saxagliptindemonstrated
increases in mean postprandial insulin
AUC and C-peptide AUC levels versus
metformin plus placebo (supplementary
Figure A2a and b, available in an online
appendix). The change from baseline in
postprandial glucagon AUC at week 24
revealed a greater decrease for all saxa-
gliptin doses versus metformin plus pla-
cebo without any apparent dose
dependency.The95%CIfortheplacebo-
subtracted adjusted mean change from
baseline for postprandial insulin AUC,
glucagon AUC, and C-peptide AUC ex-
cluded zero for all saxagliptin treatment
groups (Table 1). -Cell function, calcu-
lated using HOMA-2 (20), improved in
all saxagliptin treatment groups at week
24 (Table 1). Differences in adjusted
mean changes from baseline versus met-
formin plus placebo (95% CI) were
11.5% (5.4–17.7), 12.7% (6.6–18.8),
and 13.1% (7.0–19.3) for the 2.5, 5, and
10 mg saxagliptin groups, respectively.
Patients treated with saxagliptin had de-
creases in fasting glucagon measurements
of greater magnitude than those observed
for metformin plus placebo (data not
shown, NS). No discernible effects on
fasting C-peptide and insulin levels were
observed for saxagliptin versus met-
formin plus placebo.
The early insulin response based on
the insulinogenic index, calculated as
	I0–30 min/	G0–30 min,andinsulinsensitivity,
calculated using the oral glucose insulin sen-
sitivity(OGIS)index,increasedinallsaxaglip-
tin treatment groups at week 24 (Table 1). No
signiﬁcanttreatmenteffectwasobservedinthe
HOMA-2 insulin resistance index or the Mat-
suda index of insulin sensitivity at week 24.
Mean changes from baseline in body weight at
week 24 were 1.43, 0.87, and 0.53 kg
for2.5,5,and10mgsaxagliptinversus0.92
kgformetforminplusplacebo.Effectsofsaxa-
gliptinonBMI,meanwaistcircumference,and
mean fasting lipid levels were similar to those
for metformin plus placebo.
Figure 1—Effect of saxagliptin added to metformin versus placebo added to metformin. A: A1C
meanchangefrombaselinevalues(lastobservationcarriedforward[LOCF])duringthe24-week
treatment period. B: Mean fasting plasma glucose values (LOCF) during the 24-week treatment
period. C: Postprandial glucose 3-h AUC during the OGTT (LOCF): baseline versus week 24.
Saxagliptin added to metformin therapy
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ued the study for lack of glycemic control or
who were rescued for unacceptable glycemic
control was approximately 2 times higher for
metformin plus placebo (27.4%) versus saxa-
gliptin (14.6, 12.6, and 14.9% for 2.5, 5, and
10 mg saxagliptin, respectively). Conse-
quently,meandurationofexposuretodouble-
blind study medication was similar across the
saxagliptin treatment groups (mean range,
150–152 days) but shorter for the metformin
plus placebo group (134 days), given that res-
cued patients were entered directly into the
long-term extension.
Treatment with saxagliptin was generally
well tolerated across all doses. The percentage
of patients who had at least one adverse event
was 74.3% (saxagliptin-treated patients) ver-
sus 64.8% (metformin plus placebo group),
without evidence of a dose-response relation-
ship. Generally, the frequency of the most
common adverse events (5%) reported in
saxagliptin-treated patients was similar to that
in the metformin plus placebo group as was
the percentage of patients with one or more
serious adverse events (Table 2). No patients
had a serious adverse event that was consid-
ered to be treatment related. The overall per-
centage of patients who had skin-related
adverse events was similar for saxagliptin-
treated patients (47 patients, 8.3%) and pa-
tientsinthemetforminplusplacebogroup(14
patients,7.8%),withnoapparentdose-related
effects.Theincidenceofadverseeventsrelated
to gastrointestinal disorders was similar in pa-
tients treated with saxagliptin (23.0%) versus
placebo plus metformin (24.0%).
The overall frequency of conﬁrmed hypo-
glycemiaduringthe24-weektreatmentperiod
was similar for saxagliptin-treated patients
(0.5%) and metformin plus placebo–treated
patients (0.6%). No dose relationship was ob-
servedamongthethreesaxagliptingroups.All
events were of mild or moderate intensity and
did not require treatment or medical interven-
tion (Table 2).
The 2.5- and 5-mg doses of saxagliptin
had no discernible effect on mean absolute
lymphocyte count. There was a small numer-
ical decrease from baseline in mean absolute
lymphocyte count in the 10 mg saxagliptin
group (0.14 
 10
3 cells/l) without evi-
dence of clinical sequelae. Mean lymphocyte
counts remained well within normal limits
throughoutthestudy.Thereisnoknownclin-
icalsigniﬁcancetotheﬁndingsobservedinthe
10 mg saxagliptin treatment group. Other
safety laboratory parameters, including hema-
tological, hepatic, renal, and musculoskeletal
tests, showed no drug-related issues.
CONCLUSIONS — The current
study demonstrated that saxagliptin once
daily in combination with ongoing met-
formin for 24 weeks provided clinically
relevant and statistically signiﬁcant re-
ductions in A1C versus placebo in pa-
tients with type 2 diabetes inadequately
controlled with metformin alone. A1C
reductions across all saxagliptin dose
groups were seen as early as week 4,
reached a maximum at approximately
week 12, and were maintained through-
out the remaining 12 weeks. Saxagliptin
at all doses also led to clinically meaning-
ful and statistically signiﬁcant reductions
in FPG and PPG AUC. Maximal A1C,
FPG, and PPG AUC reductions were ob-
served with the 5 mg saxagliptin dose,
without evidence of a dose-response rela-
tionship above the threshold 5-mg dose.
The lack of a dose-response relationship
at doses above 5 mg was noted previously
(16) and is likely to reﬂect similar inhibi-
Table 2—Adverse events in double-blind treatment period: total, serious, deaths, discontinuations, most frequent (>5%), reported hypogly-
cemia, conﬁrmed hypoglycemia, and exposure to study medication
PBO  MET
2.5 mg SAXA 
MET
5 mg SAXA 
MET
10 mg SAXA 
MET
Total SAXA 
MET
n 179 192 191 181 564
Adverse event 116 (64.8) 153 (79.7) 134 (70.2) 132 (72.9) 419 (74.3)
Serious adverse event 5 (2.8) 5 (2.6) 8 (4.2) 5 (2.8) 18 (3.2)
Deaths* 1 (0.6) 0 0 0 0
Discontinuation due to adverse event 2 (1.1) 5 (2.6) 6 (3.1) 5 (2.8) 16 (2.8)
Adverse events 5%†
Nasopharyngitis 14 (7.8) 18 (9.4) 13 (6.8) 18 (9.9) 49 (8.7)
Headache 13 (7.3) 18 (9.4) 11 (5.8) 16 (8.8) 45 (8.0)
Diarrhea 20 (11.2) 19 (9.9) 11 (5.8) 10 (5.5) 40 (7.1)
URI 9 (5.0) 13 (6.8) 9 (4.7) 15 (8.3) 37 (6.6)
Inﬂuenza 13 (7.3) 12 (6.3) 12 (6.3) 10 (5.5) 34 (6.0)
UTI 8 (4.5) 10 (5.2) 10 (5.2) 9 (5.0) 29 (5.1)
Arthralgia 5 (2.8) 8 (4.2) 8 (4.2) 9 (5.0) 25 (4.4)
Back pain 12 (6.7) 11 (5.7) 5 (2.6) 8 (4.4) 24 (4.3)
Hypertension 6 (3.4) 11 (5.7) 4 (2.1) 5 (2.8) 20 (3.5)
Cough 6 (3.4) 10 (5.2) 6 (3.1) 3 (1.7) 19 (3.4)
Dyspepsia 6 (3.4) 4 (2.1) 10 (5.2) 4 (2.2) 18 (3.2)
Pain in extremity 10 (5.6) 5 (2.6) 4 (2.1) 8 (4.4) 17 (3.0)
Reported hypoglycemia 9 (5.0) 15 (7.8) 10 (5.2) 7 (3.9) 32 (5.7)
Conﬁrmed hypoglycemia 1 (0.6) 1 (0.5) 1 (0.5) 1 (0.6) 3 (0.5)
Exposure (days) 134  54.4 152  42.8 150  44.3 151  40.2
Data are n (%) or means  SD. Treated patients dataset. An adverse event was deﬁned as any new or worsening illness, sign, symptom, or clinically signiﬁcant
laboratory test abnormality as noted by the investigator during the course of the study, regardless of the investigator’s attribution of the event to study treatment.
Conﬁrmed hypoglycemia is deﬁned by symptoms of hypoglycemia in the setting of a ﬁngerstick blood glucose value 50 mg/dl. Extent of exposure is deﬁned as
thetimefromtheﬁrstdaytothelastday,inclusive,thatapatienttookdouble-blindstudymedicationduringthe24-weekshort-termtreatmentperiod.*Deathfrom
cardiogenic shock. †Hypoglycemia events excluded. MET, metformin; PBO, placebo; SAXA, saxagliptin; URI, upper respiratory tract infection; UTI, urinary tract
infection.
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doserangestudied.Giventhatsaxagliptin
administered as monotherapy also pro-
duced greater A1C reductions versus pla-
cebo and in the same general range as the
current study suggests that the actions of
saxagliptin are direct and are not reﬂec-
tive of a restoration of the sensitizing abil-
ity of metformin.
Notably, the percentage of patients
who achieved an A1C 7% was more
than 2 times greater in patients who re-
ceived saxagliptin than in patients who
received metformin plus placebo. This
ﬁndingisparticularlyimportantgiventhe
inadequate glycemic control observed in
a high proportion of patients with type 2
diabetes in real-world settings. The inci-
dence of microvascular complications
from diabetes has been shown to be
meaningfully reduced with each 1% re-
duction in A1C; thus, it is reasonable to
suggest that saxagliptin added to met-
formin therapy would yield clinical ben-
eﬁts in terms of risk reduction (21).
Asisfrequentlyobservedwithantihy-
perglycemic agents, greater A1C reduc-
tions were seen in patients with higher
baseline A1C values and were most evi-
dent for the 2.5 and 5 mg saxagliptin
groups. Importantly, the effect of saxa-
gliptin on A1C lowering was consistent
acrossallthreetreatmentgroupsforother
prespeciﬁedsubgroups,suggestingitsap-
propriateness across a variety of patients
with type 2 diabetes. FPG reductions and
percentage of patients achieving a tar-
geted A1C glycemic response in the 5 mg
saxagliptin arm were within the range of
similar DPP-4 inhibitor add-on to met-
formin studies with sitagliptin, vildaglip-
tin, and alogliptin, although the absence
of head-to-head comparisons precludes
deﬁnitive conclusions. In general, DPP-4
inhibitors in combination with met-
formin demonstrate enhanced glycemic-
lowering efﬁcacy versus comparators
without a signiﬁcant increase in associ-
ated hypoglycemia or weight gain
(13,15,22).
The incretin hormones GLP-1 and
GIParesecretedinresponsetoenteralnu-
trient stimulation. Saxagliptin is thought
to exert its actions by slowing the inacti-
vation of incretin hormones through in-
hibitionofDPP-4,therebyenhancingand
prolonging incretin function. This results
in an improvement in glucose-mediated
insulin release and a reduction in post-
prandial glucagon secretion (4). Consis-
tent with this mechanism, treatment
with saxagliptin also led to statistically
signiﬁcant decreases in PPG that were as-
sociated with greater increases in post-
prandial insulin and C-peptide AUC
levels versus metformin plus placebo,
suggesting that saxagliptin improved
postprandial-cellresponsivenesstoglu-
cose. Saxagliptin added to metformin was
also associated with -cell function im-
provements as assessed by HOMA-2.
HOMA-2 improvements, based on fast-
ing indexes of glucose and insulin levels,
may represent enhancement of basal in-
cretinactionand/orameliorationof-cell
glucotoxicity. Further, treatment with
saxagliptin produced a greater decrease
from baseline in postprandial glucagon
AUC versus placebo. This greater sup-
pression of glucagon secretion also may
havecontributedtothereductioninpost-
prandialhyperglycemiabydecreasinghe-
patic glucose output. Although the OGIS
index of insulin sensitivity improved, the
Matsuda index did not change. More sen-
sitive indicators of insulin action are re-
quired to draw deﬁnitive conclusions on
the effect of saxagliptin on insulin
sensitivity.
Generally, treatment with saxagliptin
plusmetforminwaswelltoleratedover24
weeks.Althoughtheoverallpercentageof
patients with adverse events was numeri-
cally higher in the saxagliptin treatment
groups, the metformin plus placebo
group had a shorter mean duration of ex-
posure to the study medication and con-
sequently a shorter mean time of risk for
experiencing adverse events than the
saxagliptin treatment groups. There was
no evidence for a dose-response relation-
ship for adverse events. The incidence of
skin-related adverse events was similar
for the metformin plus saxagliptin treat-
ment groups relative to the metformin
plus placebo group. This result is of par-
ticular importance given that certain der-
mal toxicities have been associated with
the DPP-4 inhibitor class; however, in the
absence of a direct comparison, speciﬁc
conclusions cannot be drawn as longer
observation periods in a greater number
of patients may yield different results
(23,24). In keeping with the mechanism
of action of saxagliptin, the addition of
saxagliptin to metformin did not increase
theincidenceofhypoglycemiaversusthat
with metformin alone, which is relevant
asuseofDPP-4inhibitorsincombination
regimens becomes more accepted (3,25).
Study limitations included differ-
ences in exposure time for the saxagliptin
treatment groups versus the metformin
plus placebo group, which may have in-
ﬂuenced adverse event occurrence rates.
Only data before rescue were used for ef-
ﬁcacy and safety analyses, which may
have also affected the results.
Saxagliptin added to metformin pro-
duced clinically and statistically signiﬁ-
cant improvements in A1C, FPG, and
PPG. Statistically signiﬁcant improve-
ments in -cell function as well as a re-
duction of glucagon were also
demonstrated. Treatment across all saxa-
gliptin groups was generally well toler-
ated with no increase in weight or
hypoglycemia compared with metformin
plus placebo. Taken together, these re-
sults suggest that saxagliptin represents a
valuable therapeutic option for the man-
agement of patients with type 2 diabetes
inadequately controlled with metformin
monotherapy.
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